Go Deep
Voyager Therapeutics, Inc.
Voyager Therapeutics, Inc. Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | 22,015 | -1.2 | 0.86 | 0.21 | 204.75 |
| Oct 2026 | 22,170 | -1.1 | 0.80 | 0.21 | 190.84 |
| Oct 2026 | 22,114 | -1.2 | 0.82 | 0.21 | 195.62 |
| Oct 2026 | 22,269 | -1.1 | 0.76 | 0.21 | 179.96 |
| Oct 2026 | 22,102 | -1.1 | 0.82 | 0.21 | 194.37 |
| Oct 2026 | 21,946 | -1.2 | 0.87 | 0.21 | 207.65 |
| Oct 2026 | 22,135 | -1.1 | 0.81 | 0.21 | 191.06 |
| Oct 2026 | 22,313 | -1.0 | 0.74 | 0.21 | 175.57 |
| Oct 2026 | 22,447 | -1.0 | 0.69 | 0.21 | 164.92 |
Voyager Therapeutics, Inc. Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 3,165,000.0 | 2,593,000.0 | 15,336,000.0 | 13,365,000.0 |
| Net Profit | -24,473,000.0 | -27,937,000.0 | -27,426,000.0 | -27,892,000.0 |
| EPS | -0.4 | -0.5 | -0.5 | -0.5 |
Voyager Therapeutics, Inc. Revenue & Profit: Last 4 Years
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Revenue | 40,374,000.0 | 80,001,000.0 | 250,008,000.0 | 40,907,000.0 |
| Net Profit | -119,721,000.0 | -65,002,000.0 | 132,330,000.0 | -46,408,000.0 |
| EPS | -2.0 | -1.1 | 3.1 | -1.2 |
Voyager Therapeutics, Inc. Balance Sheet
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Total Assets | 252,281,000.0 | 393,050,000.0 | 351,281,000.0 | 159,356,000.0 | — |
| Total Liabilities | 56,200,000.0 | 93,290,000.0 | 114,961,000.0 | 100,336,000.0 | — |
| Total Equity | 196,081,000.0 | 299,760,000.0 | 236,320,000.0 | 59,020,000.0 | — |
Owes vs Owns
Voyager Therapeutics, Inc. owed $0.22 for every $1 it owned in Jun 2026, down from $0.63 in Dec 2022.
| Period | Jun 2026 | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
| Owes vs Owns | 0.22× | 0.22× | 0.24× | 0.33× | 0.63× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
Voyager Therapeutics, Inc. Assets & Liabilities Breakdown (USD millions)
What it owns — Dec 2025
Cash & short-term investments 77.9%Receivables 1.2%Fixed assets (tangible) 16.5%Long-term investments 2.1%Other assets 2.4%
How it's funded — Dec 2025
Short-term debt 3.1%Long-term debt 11.4%Payables 2.0%Other liabilities 5.8%Shareholders' equity 77.7%
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 196.4 | 266.7 | 230.9 | 118.8 |
| Receivables | 2.9 | 4.5 | 84.5 | 0.6 |
| Inventory | 0.0 | 0.0 | 0.0 | 0.0 |
| Fixed assets (tangible) | 41.6 | 47.7 | 30.0 | 33.3 |
| Intangible assets | 0.0 | 0.0 | 0.0 | 0.0 |
| Long-term investments | 5.2 | 65.7 | 0.0 | 0.0 |
| Other assets | 6.1 | 8.5 | 5.9 | 6.5 |
| Liabilities & equity | ||||
| Short-term debt | 7.8 | 7.2 | 3.2 | 2.8 |
| Long-term debt | 28.7 | 36.5 | 17.1 | 20.3 |
| Payables | 5.0 | 4.0 | 1.6 | 2.6 |
| Other liabilities | 14.7 | 45.6 | 93.1 | 74.6 |
| Shareholders' equity | 196.1 | 299.8 | 236.3 | 59.0 |
| Net tangible assets | 196.1 | 299.8 | 236.3 | 59.0 |
Voyager Therapeutics, Inc. Cash Flow
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Operating Activities | -132,467,000.0 | -15,310,000.0 | 77,919,000.0 | -12,509,000.0 | — |
| Investing Activities | 125,446,000.0 | -94,859,000.0 | -141,643,000.0 | -7,339,000.0 | — |
| Financing Activities | 816,000.0 | 114,015,000.0 | 33,645,000.0 | 1,110,000.0 | — |